Skip to content

A single-center clinical trial of topical application of propranolol for the prevention of stress or anxiety-induced hair loss

A single-center clinical trial of topical application of propranolol for the prevention of stress or anxiety-induced hair loss

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068541
Enrollment
Unknown
Registered
2023-02-22
Start date
2022-08-22
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress or anxiety-induced hair loss

Interventions

propranolol group:Use propranolol twice a day, once in the morning and once in the evening, each time use 10 sprays (1 mL in total) on the scalp
each time you spray, the scalp should be exposed as much as possible, and after spraying, the scalp should be fully massaged 3 minutes to promote absorption

Sponsors

Guangdong Second Provincial General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Clinically diagnosed as psychological anxiety, work pressure, irregular work schedule and/or anxiety caused by increased hair loss symptoms; The course of the disease is less than half a year; Patients aged 18 to 65 years with hair loss of less than 40% of the scalp area, who signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to propranolol hydrochloride or ethanol or menthol or alcohol 2. Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney, endocrine or hematopoietic system 3. Those with other scalp diseases or hair loss diseases. 4. Those with severe psychosis, cognitive impairment. 5. Those with poor systemic nutritional status and low immune function. 6. Those who have systematically used corticosteroids, immunosuppressants, cytotoxic drugs and peripheral vasodilators within 1 year. 7. Within 6 months, those who have used systemic or local drugs for hair loss, such as finasteride, minoxidil, etc.. 8. Those who have received other clinical trial drugs within 3 months. 9. Pregnant or planning to become pregnant women andlactating women. 10. Have poor compliance, family history of genetic disease, or other criteria deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
The number of hairs shed when shampooing;

Countries

China

Contacts

Public ContactYunsong Zhang

Guangdong Second Provincial General Hospital

yszhang0203@163.com+86 13926201601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026